euro adhoc: Sartorius AG / quarterly or semiannual financial statement / Order intake rose 5.7%; currency-adjusted: +8.5% / Sales revenue at the level of the strong year-earlier quarter (-0.8%); curre

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Preliminary Figures for the First Quarter of 2007

18.04.2007

In the first quarter of fiscal 2007, order intake for the Sartorius
Group rose 5.7% (currency-adjusted: +8.5%) to EUR140.2 million (Q1
2006: EUR132.7 mn). This considerable increase in order intake can be
especially attributed to double-digit growth in the filter business,
which resulted in a 6.9% currency-adjusted gain in orders for the
Biotechnology Division. For the Mechatronics Division, high growth in
the industrial scale business generated a currency-adjusted plus of
10.3% in order intake.

At EUR127.6 mn, Group sales revenue was approximately at the level of
the excellent year-earlier quarter (EUR128.6 mn). Currency-adjusted
consolidated sales revenue grew 1.6%. Here, sales revenue for the
Mechatronics Division rose 1.5% (currency-adjusted: +4.0%) to EUR61.3
mn (Q1 2006: EUR60.4 mn). With high growth rates in the filter
business and an overall excellent order situation reported for the
Biotechnology Division, its sales revenue dipped 2.8%
(currency-adjusted: -0.5%) to EUR66.3 mn (Q1 2006: EUR68.2 mn)
because of the lower project business with fermenters and
bioreactors.

Earnings included expenses of approx. EUR0.5 mn for the carve-out of
the Biotechnology Division entailed by the Stedim transaction. As a
result, earnings before interest, taxes, depreciation and
amortization (EBITDA) fell from EUR16.4 mn to EUR16.0 mn.
Accordingly, at EUR11.0 mn, EBIT was also slightly below the previous
year’s figure of EUR11.7 mn. With its EBIT margin remaining unchanged
at 10.7%, the Biotechnology Division achieved an EBIT of EUR7.1 mn,
which is approximately at the level of the year-earlier quarter
(EUR7.3 mn). At the same time, due to the product mix, EBIT for the
Mechatronics Division eased EUR0.4 mn to EUR4.0 mn; its EBIT margin
fell from 7.3% to 6.5%. The consolidated EBIT margin was 8.7% (Q1
2006: 9.1%).

Considering the substantial rise in order intake and the further
increase in order backlog, we expect significant gains in sales
revenue and earnings during the further course of the year, and
confirm our targets. Taking the projected Stedim transaction for
fiscal 2007 into account, these targets forecast an increase in pro
forma consolidated sales revenue to between EUR660 and EUR680 mn.
Organic growth (without Stedim) is prognosticated to be at approx.
10%. The operating EBIT margin, excluding transaction and integration
costs of about EUR5-10 mn, is anticipated to climb to approx. 12%
(without Stedim, to around 11%). For the period up to 2011, we assume
that the compound annual growth rate (CAGR) will be at 11%-12%
(without Stedim, approx. 10%), with a simultaneous further increase
in profitability.

Because the Biotechnology Division is being carved out, we will be
publishing the complete quarterly report somewhat later than
originally planned, tentatively on April 25, 2007.

end of announcement euro adhoc 18.04.2007 21:15:28
--------------------------------------------------------------------------------

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Andreas Wiederhold
Treasury & Investor Relations
Telefon: +49 (0)551 308-1668
E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / official dealing/prime standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bayerische Börse / free trade
Niedersächsische Börse zu Hannover / official dealing